Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer |
Lee, Kangwook
(Department of Clinical Oncology, Cheonan Korean Medical Hospital, Daejeon University)
Ryu, Juyoung (Department of Clinical Oncology, Cheonan Korean Medical Hospital, Daejeon University) Son, Chang-Gue (Liver and Immunology Research Center, Daejeon Korean Medical Hospital, Daejeon University) Cho, Jung-Hyo (Liver and Immunology Research Center, Daejeon Korean Medical Hospital, Daejeon University) Yoo, Hwa-Seung (East West Cancer Center, Dunsan Korean Medical Hospital, Daejeon University) Lee, Jonghoon (Department of Integrative Cancer Center, Woosuk Korean Medicine Hospital, Woosuk University) Kim, Yoon-sik (Department of Internal Medicine, Cheonan Korean Medical Hospital, Daejeon University) Lee, Namhun (Department of Clinical Oncology, Cheonan Korean Medical Hospital, Daejeon University) |
1 | Whang CY. [Bibliographic study on the therapy of lung cancer by integrated oriental and western medicine]. J Korean Orient Med. 1995;16(2):177-94. Korean. |
2 | Bang SH, Yoon JW, Cho CK, Shin JE, Lee YW, Yoo HS. A case series of survival outcomes in patients with advanced-stage IIIb/IV non-small-cell lung cancer treated with HangAm-plus. J Pharmacopuncture. 2012;15(2):31-5. DOI |
3 | Yim MH, Shin JW, Son JY, Oh SM, Han SH, Cho CK, et al. Soluble components of Hericium erinaceum induce NK cell activation via production of interleukin-12 in mice splenocytes. Acta Pharmacol Sin. 2007;28(6):901-7. DOI |
4 | Bi X, Xia X, Mou T, Jiang B, Fan D, Wang P, et al. Anti-tumor activity of three ginsenoside derivatives in lung cancer is associated with Wnt/beta-catenin signaling inhibition. Eur J Pharmacol. 2014;742:145-52. DOI |
5 | Cheon SH, Kim KS, Kim S, Jung HS, Choi WC, Eo WK. Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer. Forsch Komplementmed. 2011;18(2):77-83. |
6 | Park SJ, Kang HJ, Park JH, Cho CK, Yoo HS. [A case report of a clinically diagnosed advanced lung cancer patient after treatment with gunchilgyebok-jung]. J Korean Tradit Oncol. 2015;20(1):23-9. Korean. |
7 | Mok TS, Wu YL, Yang CH, Chu DT, Saijo N, Sunpaweravong P, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57. DOI |
8 | Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, et al. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Trials. 2015;16:146. DOI |
9 | Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281-9. DOI |
10 | Yang L, Wang L, Zhang Y. Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol. 2016;5(1):1-20. |
11 | Ansari J, Shackelford RE, El-Osta H. Epigenetics in nonsmall cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. 2016;5(2):155-71. DOI |
12 | Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study. Complement Ther Med. 2014;22(6):1010-8. DOI |
13 | Li MJ, He Q, Li M, Luo F, Guan YS. Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther. 2016;9:1291-302. |
14 | Beom SH, Kim DW, Sim SH, Keam B, Park JH, Lee JO, et al. Gefitinib-induced interstitial lung disease in Korean lung cancer patients. Cancer Res Treat. 2016;48(1):88-97. DOI |